$ATNM phase 3 @ 50% enrollment results 82% failure for the primary endpoint in the control arm vs 80% success of lomab -B. Very high probability of success $mteh $ccxi $cvm $aveo $nwbo $tgtx $kpti $bmy $mrk $mark $tlss $abbv $amgn $pfe $nvs $regn $sgen #Pennystocks #OTCStocks https://t.co/IEC1GPJKIz